NCT01908296已完成1 期
Phase I Study of FK949E - A Study of Drug-drug Interactions Between FK949E and Fluvoxamine in Healthy Male Adults
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 24
- 主要终点
- Maximum plasma concentration (Cmax) of unchanged quetiapine
研究概览
简要总结
The objective of the study was to assess the effect of multiple-dose fluvoxamine on the pharmacokinetics of quetiapine (FK949E) in healthy adult male subjects. The safety of FK949E in the population was also evaluated.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Other
- 盲法
- None
入排标准
- 年龄范围
- 20 Years 至 44 Years（Adult）
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- •Body weight : ≥50.0 kg, <80.0 kg
- •Body Mass Index : ≥17.6, <26.4
- •Healthy, as judged by the investigator/subinvestigator based on the results of physical examinations (subjective symptoms and objective findings) and all tests obtained at screening and during the period from hospital admission to immediately before study medication
排除标准
- •Subjects with the following history.
- •Hepatic disease (e.g. viral hepatitis, drug-induced liver injury).
- •Heart disease (e.g. congestive heart failure, angina pectoris, arrhythmia requiring
- •treatment).
- •Respiratory disease (e.g. serious bronchial asthma, chronic bronchitis)
- •Gastrointestinal disease (e.g. serious peptic ulcer, gastroesophageal reflux esophagitis;
- •diseases requiring several selections except for appendicitis)
- •Renal disease (e.g. acute renal failure, glomerulonephritis, interstitial nephritis).
- •Cerebrovascular disorder (e.g. cerebral infarction).
- •Malignant tumor.
- •Drug allergies. Allergic disorders (except for hay fever)
- •Drug dependence, alcohol dependence
- •Any disease (except dental caries)
- •A deviation from the normal reference range of blood pressure, pulse rate, body temperature, or 12-lead ECG
- •A deviation of the following criteria for clinical laboratory tests.
- •The normal reference ranges specified at the study site will be used as the normal reference ranges in the present study.
- •Hematology:
- •A deviation of ±20% from the upper or lower limit of the normal range
- •Blood biochemistry:
- •A deviation from the normal range for AST, ALT, creatinine (Cre), HbA1c or serum electrolytes.
- •A deviation of ±20% from the upper or lower limit of the normal range for other items than the above.
- •However, the lower limit of the normal range will not be established for items for which a deviation from the lower limit is not considered clinically significant[AST, ALT, total bilirubin (T-Bil), ALP, γ-GTP, LDH, CK, Cre, uric acid (UA), BUN, and total cholesterol (T-Cho)].
- •Urinalysis:
- •U-Glc and/or U-Pro results of (±) or worse
- •U-Uro results of (+) or worse
- •Urinary drug test:
- •A positive result for phencyclidine, benzodiazepine, cocaine, amphetamines, cannabis, opiates, barbiturates or tricyclic antidepressants
- •Immunological test:
- •A positive result for hepatitis B, hepatitis C, syphilis, or HIV
- •History of treatment, including medication, within 14 days before the start of study drug administration
- •Consumption of food or beverages containing St. John's Wort within 14 days before the start of study drug administration, or consumption of grapefruit
- •Previous participation in a pre- or post-marketing clinical study of another prescription drug or a medical device within 120 days before the study
- •History of administration of quetiapine
- •History of administration of fluvoxamine
- •Whole blood sampling of 400 mL or more within 90 days before the screening assessment, whole blood sampling of 200 mL or more within 30 days before the screening assessment, or blood component donation within 14 days before the screening assessment
- •Routine excessive alcohol consumption ("excessive alcohol" is defined as an average of 45 g of alcohol per day [cf., a large bottle of beer containing 25 g of alcohol, 180 mL of sake containing 22 g of alcohol])
- •Subjects with a smoking habit (except those who quit smoking at least 90 days before the screening assessment)
研究组 & 干预措施
FK949E group
Experimental
receiving FK949E with and without fluvoxamine
干预措施: FK949E (Drug)
FK949E group
Experimental
receiving FK949E with and without fluvoxamine
干预措施: fluvoxamine (Drug)
结局指标
主要结局
Maximum plasma concentration (Cmax) of unchanged quetiapine
时间窗: For 48 hours after dosing.
AUC (area under the curve) of unchanged quetiapine
时间窗: For 48 hours after dosing.
次要结局
- tmax of plasma concentration of unchanged quetiapine(For 48 hours after dosing.)
- t1/2 of plasma concentration of unchanged quetiapine(For 48 hours after dosing.)
- Maximum plasma concentration (Cmax) of quetiapine metabolites(For 48 hours after dosing.)
- AUC (area under the curve) of quetiapine metabolites(For 48 hours after dosing.)
- tmax of plasma concentration of quetiapine metabolites(For 48 hours after dosing.)
- t1/2 of plasma concentration of quetiapine metabolites(For 48 hours after dosing.)
- Maximum plasma concentration (Cmax) of unchanged fluvoxamine(For 12 hours after dosing.)
- AUC (area under the curve) of unchanged fluvoxamine(For 12 hours after dosing.)
- tmax of plasma concentration of unchanged fluvoxamine(For 12 hours after dosing.)
- t1/2 of plasma concentration of unchanged fluvoxamine(For 12 hours after dosing.)
- Safety assessed by the incidence of adverse events, clinical tab tests, vital signs, 12-lead ECGs and physical exam(Up to 20 Days.)
研究者
相似试验
已完成
1 期
Drug-Drug Interaction of ASN51 With Fluvoxamine, Itraconazole and Paroxetine in Healthy SubjectsDrug Drug InteractionNCT06232109Asceneuron S.A.50
已完成
1 期
Study to Evaluate Safety and Tolerability of FK949E in Elderly Patients With Major Depressive DisorderMajor Depressive Disorder PatientsNCT01903200Astellas Pharma Inc16
已完成
1 期
Study to Evaluate Safety and Tolerability of FK949E in Patients With Major Depressive DisorderMajor Depressive Disorder PatientsNCT01871974Astellas Pharma Inc16
已完成
1 期
Oral Multiple-dose Study in Patients With Major Depressive DisorderMajor Depressive DisorderNCT01924520Astellas Pharma Inc32
已完成
1 期
Comparison of Plasma Concentration Changes Between Two Types of Tablets of FK949E Administration to Patients With Major Depressive DisorderMajor Depressive DisorderNCT01919008Astellas Pharma Inc16